Frank J. Palella, MD; Carl Armon, MSPH; Kate Buchacz, PhD, MPH; Stephen R. Cole, PhD; Joan S. Chmiel, PhD; Richard M. Novak, MD; Kathleen Wood, BSN; Anne C. Moorman, BSN; John T. Brooks, MD; HOPS (HIV Outpatient Study) Investigators
Palella FJ, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, et al. The Association of HIV Susceptibility Testing With Survival Among HIV-Infected Patients Receiving Antiretroviral Therapy: A Cohort Study. Ann Intern Med. 2009;151:73-84. doi: 10.7326/0003-4819-151-2-200907210-00003
Download citation file:
Published: Ann Intern Med. 2009;151(2):73-84.
HIV-1 genotypic and phenotypic susceptibility testing (GPT) optimizes antiretroviral selection, but its effect on survival is unknown.
To evaluate the association between GPT and survival.
10 U.S. HIV clinics.
2699 HIV-infected patients eligible for GPT (plasma HIV RNA level >1000 copies/mL) seen from 1999 through 2005.
Demographic characteristics, clinical factors, GPT use, all-cause mortality, and crude and adjusted hazard ratios (HRs) for the association of GPT with survival.
Patients were followed for a median of 3.3 years; 915 (34%) had GPT. Patients who had GPT had lower mortality rates than those who did not (2.0 vs. 2.7 deaths per 100 person-years). In standard Cox models, GPT was associated with improved survival (adjusted HR, 0.69 [95% CI, 0.51 to 0.94]; PÂ = 0.017) after controlling for demographic characteristics, CD4+ cell count, HIV RNA level, and intensity of clinical follow-up. In subgroup analyses, GPT was associated with improved survival for the 2107 highly active antiretroviral therapy (HAART)â€“experienced patients (2.2 vs. 3.2 deaths per 100 person-years for patients who had GPT vs. those who did not have GPT; adjusted HR, 0.60 [CI, 0.43 to 0.82]; PÂ = 0.002) and for the 921 triple antiretroviral classâ€“experienced patients (2.1 vs. 3.1 deaths per 100 person-years; adjusted HR, 0.61 [CI 0.40 to 0.93]; PÂ = 0.022). Marginal structural models supported associations between GPT and improved survival in the overall cohort (adjusted HR, 0.54; PÂ = 0.001) and in the HAART-experienced group (adjusted HR, 0.56; PÂ = 0.003).
Use of GPT was not randomized. Residual confounding may exist.
Use of GPT was independently associated with improved survival among HAART-experienced patients.
Centers for Disease Control and Prevention.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, HIV.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only